These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29668748)

  • 61. Provider perspectives on drug-resistant tuberculosis and human immunodeficiency virus care in South Africa: a qualitative case study.
    Daftary A; Padayatchi N
    Int J Tuberc Lung Dis; 2016 Nov; 20(11):1483-1488. PubMed ID: 27776589
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis.
    Gomez GB; Dowdy DW; Bastos ML; Zwerling A; Sweeney S; Foster N; Trajman A; Islam MA; Kapiga S; Sinanovic E; Knight GM; White RG; Wells WA; Cobelens FG; Vassall A
    BMC Infect Dis; 2016 Dec; 16(1):726. PubMed ID: 27905897
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Undertreated HIV and drug-resistant tuberculosis at a referral hospital in Irkutsk, Siberia.
    Heysell SK; Ogarkov OB; Zhdanova S; Zorkaltseva E; Shugaeva S; Gratz J; Vitko S; Savilov ED; Koshcheyev ME; Houpt ER
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):187-92. PubMed ID: 26792470
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neurocognitive Impairment Risk Among Individuals With Multiple Drug-Resistant Tuberculosis and Human Immunodeficiency Virus Coinfection: Implications for Systematic Linkage to and Retention of Care in Tuberculosis/Human Immunodeficiency Virus Treatment.
    Tomita A; Ramlall S; Naidu T; Mthembu SS; Padayatchi N; Burns JK
    J Nerv Ment Dis; 2019 Apr; 207(4):307-310. PubMed ID: 30920478
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
    Pablos-Mendez A; Gowda DK; Frieden TR
    Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Statistical factors associated with utilisation of ototoxicity monitoring services for multi-drug-resistant tuberculosis patients in the Western Cape.
    Ramma L; Nhokwara PT; Rogers C
    S Afr J Commun Disord; 2019 Jan; 66(1):e1-e6. PubMed ID: 30843411
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting.
    Vella V; Racalbuto V; Guerra R; Marra C; Moll A; Mhlanga Z; Maluleke M; Mhlope H; Margot B; Friedland G; Shah NS; Gandhi NR
    Int J Tuberc Lung Dis; 2011 Sep; 15(9):1170-5, i. PubMed ID: 21943840
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: experience from rural South Africa.
    Floyd K; Wilkinson D; Gilks C
    BMJ; 1997 Nov; 315(7120):1407-11. PubMed ID: 9418087
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Community-based management of multidrug-resistant tuberculosis in South Africa.
    Bekker LG; Wood R
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):379. PubMed ID: 20202291
    [No Abstract]   [Full Text] [Related]  

  • 70. Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa.
    Andrews JR; Shah NS; Gandhi N; Moll T; Friedland G;
    J Infect Dis; 2007 Dec; 196 Suppl 3():S482-90. PubMed ID: 18181698
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A pilot study of an mHealth application for healthcare workers: poor uptake despite high reported acceptability at a rural South African community-based MDR-TB treatment program.
    Chaiyachati KH; Loveday M; Lorenz S; Lesh N; Larkan LM; Cinti S; Friedland GH; Haberer JE
    PLoS One; 2013; 8(5):e64662. PubMed ID: 23724075
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost-effectiveness of a medication event monitoring system for tuberculosis management in Morocco.
    Yang J; Kim HY; Park S; Sentissi I; Green N; Oh BK; Kim Y; Oh KH; Paek E; Park YJ; Oh IH; Lee SH
    PLoS One; 2022; 17(4):e0267292. PubMed ID: 35439273
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Community- vs. hospital-based management of multidrug-resistant TB in Pakistan.
    Fatima R; Yaqoob A; Qadeer E; Khan MA; Ghafoor A; Jamil B; Haq MU; Ahmed N; Baig S; Rehman A; Abbasi Q; Khan AW; Ikram A; Hicks JP; Walley J
    Int J Tuberc Lung Dis; 2022 Oct; 26(10):929-933. PubMed ID: 36163662
    [No Abstract]   [Full Text] [Related]  

  • 74. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cost-consequence analysis of ambulatory clinic- and home-based multidrug-resistant tuberculosis management models in Eswatini.
    Peresu E; De Graeve D; Heunis JC; Kigozi NG
    PLoS One; 2024; 19(4):e0301507. PubMed ID: 38564589
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis.
    Akalu TY; Clements ACA; Wolde HF; Alene KA
    Sci Rep; 2023 Dec; 13(1):22361. PubMed ID: 38102144
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The Effect of HIV and Antiretroviral Therapy on Drug-Resistant Tuberculosis Treatment Outcomes in Eastern Cape, South Africa: A Cohort Study.
    van de Water B; Abuelezam N; Hotchkiss J; Botha M; Ramangeola L
    Viruses; 2023 Nov; 15(11):. PubMed ID: 38005919
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Organisation of care for people receiving drug-resistant tuberculosis treatment in South Africa: a mixed methods study.
    Dickson L; Le Roux SR; Mitrani L; Hill J; Jassat W; Cox H; Mlisana K; Black J; Loveday M; Grant A; Kielmann K; Ndjeka N; Moshabela M; Nicol M
    BMJ Open; 2023 Nov; 13(11):e067121. PubMed ID: 37977868
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Healthcare worker perceived barriers and facilitators to implementing a tuberculosis preventive therapy program in rural South Africa: a content analysis using the consolidated framework for implementation research.
    van de Water BJ; Wilson M; le Roux K; Gaunt B; Gimbel S; Ware NC
    Implement Sci Commun; 2023 Aug; 4(1):107. PubMed ID: 37649057
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Time-to-Treatment Initiation in a Decentralised Community-Care Model of Drug-Resistant Tuberculosis Management in the OR Tambo District Municipality of South Africa.
    Iruedo JO; Pather MK
    Int J Environ Res Public Health; 2023 Jul; 20(14):. PubMed ID: 37510655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.